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Total hip and knee arthroplasty are highly successful treatment modalities for 
advanced osteoarthritis. However, prolonged wound leakage after arthroplasty 
is linked to prosthetic joint infection (PJI), which is a potentially devastating 
complication. On the one hand, wound leakage is reported as a risk factor for 
PJI with a leaking wound acting as a porte d’entrée for microorganisms. On the 
other hand, prolonged wound leakage can be a symptom of PJI. Literature 
addressing prolonged wound leakage is scarce, contradictory and of poor 
methodological quality. Hence, treatment of prolonged wound leakage varies 
considerably with both non-surgical and surgical treatment modalities. There 
is a denite need for evidence concerning the best way to treat prolonged 
wound leakage after joint arthroplasty. 
Methods
A prospective nationwide randomized controlled trial will be conducted in 35 
hospitals in the Netherlands. The goal is to include 388 patients with persistent 
wound leakage 9-10 days after total hip or knee arthroplasty. These patients 
will be randomly allocated to non-surgical treatment (pressure bandages, 
(bed) rest and wound care) or surgical treatment (debridement, antibiotics and 
implant retention (DAIR)). DAIR will also be performed on all non-surgically 
treated patients with persistent wound leakage at day 16-17 after index surgery, 
regardless of amount of wound leakage, other clinical parameters or C-reactive 
protein. Clinical data are entered into a web-based database. Patients are asked 
to ll in questionnaires about disease-specic outcomes, quality of life and 
cost eectiveness at 3, 6 and 12 months after surgery. Primary outcome is the 
number of revision surgeries due to infection within a year of arthroplasty. 
Ethics and dissemination
The Review Board of each participating hospital has approved the local 
feasibility. The results will be published in peer-reviewed scientic journals.
Trial registration number
NTR 5960. 
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Strengths and limitations of this study
- This nationwide study is the rst randomized controlled trial to compare 
outcomes of non-surgical treatment and surgical treatment in patients with 
prolonged wound leakage after total hip and knee arthroplasty.
- This study is an initiative of the Netherlands Orthopaedic Association. 
The optimal treatment for persistent wound leakage is unknown and is 
considered an important knowledge gap. This is why numerous Dutch 
hospitals participate, allowing for inclusion of a large number of patients.
- Since literature addressing wound leakage is scarce, there is no evidence for 
the optimal timing of DAIR. Therefore, timing of the early intervention (DAIR 
at day 9-10) is based on consensus instead of evidence. 
- Orthopaedic surgeons may be reluctant to randomize patients in case of 
minimal wound leakage (LEAK class 1). This may induce biased results.




Osteoarthritis (OA) is the most common joint disorder worldwide and is 
recognized as a substantial source of disability.1 Total hip arthroplasty (THA) 
and total knee arthroplasty (TKA) are highly successful and widely accepted 
surgical treatment modalities for advanced OA of the hip and knee. In 2015, 
28,798 THAs and 27,082 TKAs were performed in the Netherlands2 and 310,800 
THAs and 693,400 TKAs were performed in the United States in 2010.3,4 The 
demand for joint arthroplasty continues to rise due to an ageing population 
and changing thresholds for surgery and is expected to keep increasing in the 
coming decades.5 Unfortunately, this results in higher absolute numbers of 
complications after joint arthroplasty. One of the most serious and potentially 
devastating complications is prosthetic joint infection (PJI). 
Persistent wound leakage after primary THA or TKA is associated with PJI. 
Wound leakage is induced in the postoperative phase by an inammatory 
response.6 Conversely, surgical wounds may also show prolonged leakage for 
other reasons (hematoma, seroma or fatty necrosis) and take longer to heal 
without development of a PJI. Prolonged wound leakage is a risk factor for 
PJI as a leaking wound can be a porte d’entrée for microorganisms (retrograde 
infection pathway).7 Bacteria can rapidly form a biolm on the metal surface 
of the prosthesis, thereby decreasing the eectiveness of the host defense 
and antimicrobial therapy. It is estimated that in the Netherlands about 
2200 patients annually (4% of ±55,000 THA/TKA) have wound leakage at 
day nine after index surgery.2,6 As PJI is a serious and potentially devastating 
complication, prolonged wound leakage should be considered as potentially 
imminent PJI, with uid production as a symptom or a risk factor for infection. 
PJI has an enormous impact on patients as well as society, as it often 
results in septic revision surgery, requiring removal of the infected implant to 
eradicate the infection and hopefully allowing subsequent re-implantation. 
This septic revision surgery is accompanied by a large negative impact on the 
quality of life of patients and high health care costs (± € 30,000 per patient 
with PJI in the United Kingdom),8 due to extended hospital stays, costly surgical 
procedures, prolonged use of antibiotics and impaired function of the hip or 
knee. The Dutch Arthroplasty Register reports a total of 3809 THA and 2667 
TKA revision surgeries performed in 2015.2 Revision surgery within one year 
of index surgery was necessary in more than 600 patients, and at least 30% of 
these were PJI-related.2 
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Persistent wound leakage can be treated by non-surgical and surgical 
treatment modalities. Non-surgical treatment can consist of relative rest (no 
exercise and bed rest), pressure bandages (hip spica or knee pressure bandage) 
and wound care with sterile bandages. Hospital admission can be required. 
Surgical treatment typically consists of debridement, antibiotics and implant 
retention (DAIR).9,10 A DAIR procedure is meant to clean the prosthesis and 
wound, including breaking down the biolm, in order to treat the infection 
and render further infection treatment unnecessary. Treatment of persistent 
wound leakage varies considerably amongst Dutch hospitals, as conrmed 
recently by a nationwide questionnaire-based survey regarding both non-
surgical and surgical treatment modalities.11 However, these modalities have 
never been studied comparatively. 
Several authors have investigated the eect of DAIR for treatment of 
persistent wound leakage and reported various results and/or made (opinion-
based) statements, generally in favor of early DAIR.6,10-15 The most recent 
PJI consensus meeting suggests ve to seven days of wound leakage as the 
threshold to perform DAIR, but there is no solid evidence for this statement.16 
Therefore, the optimal timing of DAIR is yet to be established, which could 
imply that either overtreatment or undertreatment may occur. As the treatment 
decision-making process is generally relatively easy in patients with severe 
wound leakage and a high suspicion of infection, this study particularly aims 
to provide evidence for the best treatment of patients with a low suspicion of 
infection. 
As early DAIR is hypothesized to be helpful in treating or preventing 
infection and salvaging the implant, the objective of this study is to determine 
the clinical outcome and cost eectiveness of early surgical intervention 
(DAIR at day 9-10 after index procedure) versus non-surgical treatment in 
patients with prolonged wound leakage after primary THA/TKA. In addition, 
the impact on disease-specic and general health-related quality of life will be 
determined. Our hypothesis, based on the scarce literature mentioned above, 
is that performing a DAIR at day 9-10 will result in a 50% reduction rate of 
revision surgery for PJI up to one year after primary THA/TKA compared with 
non-surgical treatment. 




Study design and procedure
A prospective nationwide multicenter randomized controlled trial (RCT) will 
be conducted. The study will be carried out in 35 hospitals throughout the 
Netherlands. All patients aged 18 or older and scheduled to undergo primary 
THA/TKA in the participating hospitals will receive written and oral information 
about the LEakage After primary Knee and hip arthroplasty (LEAK) study. 
Patients with persistent wound leakage at day 5-7 after index surgery will be 
monitored carefully and receive non-surgical treatment. Clinical examination, 
wound classication and C-reactive protein (CRP) will be carried out at day 
5-7 and day 9-10. In case of persistent leakage at day 9-10 after index surgery, 
the patient will be included in the study (after signing the informed consent 
form) and randomized to either surgical treatment (DAIR at 9-10) or continued 
non-surgical treatment. Patients allocated to the non-surgical treatment group 
with persistent wound leakage at day 16-17 after index surgery will also be 
subjected to a DAIR, regardless of amount of wound leakage, other clinical 
parameters or CRP. Patients in the non-surgical treatment group with clear 
signs of infection (dened as temperature >38.5°C, increasing wound leakage, 
redness, pain, and increasing CRP (>25% compared with day 9-10)) earlier than 
day 16-17 will receive surgical treatment at that time point. Patients with clear 
signs of infection earlier than or at day nine after index surgery will receive 
surgical treatment without randomization (Figure 1). The extended version of 
the study protocol owchart is enclosed in Figure 2 in the Appendix. 
Randomization will be performed by a web-based system (developed 
by Interactive Studios, Rosmalen, The Netherlands), based on the software 
Apache and MySQL. Each participating hospital receives an individual 
login in order to register and randomize patients. A two-day time window 
for randomization (day 9-10) is chosen to facilitate implementation of the 
protocol, as some patients undergo surgery on days of the week that result in 
follow-up moments in the weekend, which may hamper inclusion. Since there 
is no uniform classication for wound leakage, experts in the eld of PJI (the 
LEAK study group) developed a wound leakage classication system based 
on amount of wound leakage, called the LEAK classication, consisting of four 
classes: LEAK class 0: dry wound; LEAK class 1: mild wound leakage (<2x2cm in 
gauze per 24 hour); LEAK class 2: moderate wound leakage (>2x2cm in gauze 
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and no need for >1 absorbent gauze exchange per 24 hour); and LEAK class 3: 
severe wound leakage (need for >1 absorbent gauze exchange per 24 hour). 
Due to the nature of the study, patients and surgeons cannot be blinded. Data 
analyses will be performed blinded.
Figure 1. Flowchart of the LEAK study protocol
Inclusion and exclusion criteria
All patients aged 18 or older with persistent wound leakage at day 9-10 
after primary THA/TKA surgery are eligible for inclusion and subsequent 
randomization for the surgical treatment (DAIR at day 9-10) or continued non-
surgical treatment. Exclusion criteria are mental or physical disability to ful ll 
study requirements and insu  cient command of the Dutch language. 
Surgical treatment
The surgical treatment consists of DAIR at day 9-10. DAIR consists of opening the 
wound and obtaining one culture from the intra-articular synovial  uid deep 
to the fascia and at least four deep-tissue cultures: two synovial and at least 
two around the components of the joint prosthesis. Empirical antimicrobial 
treatment in accordance with the local protocol is started after obtaining 
cultures and excising hematoma and necrosis. Mobile parts (e.g. tibial insert, 
femoral head and acetabular liner) are exchanged to make room for optimal 
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debridement. The wound is extensively debrided and lavaged using 3-6 liters 
of saline (alternative is a povidone iodine solution or chlorhexidine solution). 
Mechanical scrubbing of the visible prosthetic parts is advised. 
Non-surgical treatment
The non-surgical treatment consists of relative rest (stop exercise and start bed 
rest), pressure bandages (hip spica or knee pressure bandage) and wound care 
with sterile bandages. The non-surgical treatment is optionally carried out in 
a hospital admission setting. Patients in the non-surgical treatment group do 
not receive antimicrobial treatment. In non-surgically treated patients clinical 
examination, wound classication and CRP are performed at day 16-17 after 
index surgery. A DAIR will also be performed on all patients with persistent 
wound leakage at day 16-17 after index surgery, regardless of amount of 
wound leakage, other clinical parameters or CRP. 
Outcome measures
Primary outcome is the percentage of reoperations for PJI within one year of 
index surgery. Reoperation refers to any kind of septic revision surgery (one 
or two stage revision, Girdlestone, arthrodesis or amputation). In addition, any 
other PJI treatment modalities are recorded (repeated DAIR, start of suppressive 
antimicrobial treatment or watchful neglect). 
Secondary outcomes are the impact of surgical treatment compared with 
non-surgical treatment on disease-specic outcome and general health-
related quality of life and the economic evaluation (cost eectiveness and cost 
utility) of the surgical and non-surgical treatment. Self-reported questionnaires 
will be used to measure these outcome parameters. All questionnaires used 
are recommended by the Netherlands Orthopaedic Association (NOV) as a 
quality assessment tool of orthopaedic care and are included in the standard 
Patient Reported Outcome Measure (PROM) list for both THA and TKA patients. 
Randomized patients will ll in these questionnaires 3, 6 and 12 months after 
index surgery.
Clinical data
Clinical data will be recorded from randomized patients, patients who undergo 
surgical treatment earlier or at day nine because of clear signs of infection and 
patients with persistent wound leakage at day 5-7 but a dry wound at day 9-10 
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after index surgery. Data are recorded in the web-based database. Demographic 
characteristics, body mass index, American Society of Anesthesiologists score, 
immunosuppressant medication, diabetes and anticoagulants will be recorded. 
Further data include information about the index surgery, reoperation for 
PJI, postoperative complications, clinical signs of infection, use of antibiotics 
and measurement of CRP. For those patients who are allocated to surgical 
treatment, details of the DAIR procedure and culture results will be recorded. 
In case of repeated DAIR procedures, the information will also be specied in 
the database. The clinical data are lled in by a physician of the participating 
hospital, to preserve doctor-patient condentiality.
Disease specic outcome and general health-related quality of life
Questionnaires that will be used to measure disease-specic outcome are the 
Hip and Knee disability and Osteoarthritis Outcome Score – physical function 
short form (HOOS-PS/KOOS-PS)17,18 and the Oxford Hip and Knee Score (OHS/
OKS).19,20 General health-related quality of life will be measured by the EuroQol-
5D-5L (EQ-5D-5L).21,22 
The HOOS-PS and KOOS-PS are disease-specic PROMs derived from the 
original HOOS and KOOS questionnaires. These questionnaires inform after hip 
or knee disability in patients with osteoarthritis. The HOOS-PS consists of ve 
items assessing physical function with interval-level properties. Questions are 
answered using a Likert scale, in which a higher score reects more symptoms 
and limitations. The KOOS-PS contains seven items. Questions are answered 
using a Likert scale, with higher scores indicating more limitations in physical 
functioning. The raw scores are converted to a 0-to-100 scale with 100 as the 
best outcome. The Dutch language versions of the HOOS-PS and KOOS-PS are 
considered reliable and valid.17,18 
The OHS and OKS are disease-specic PROMs. These questionnaires consist 
of twelve questions covering function and pain associated with the hip or 
knee. Questions are answered using a Likert scale. Scoring involves summating 
the total for each item to produce a nal score between 0 and 48, with a higher 
score indicating greater disability. The questionnaires are considered reliable, 
valid and sensitive to clinically important changes over time and are available 
in the Dutch language.19,20 
The EQ-5D-5L is a widely used and valid generic instrument to measure 
general health-related quality of life, and is validated in the Dutch language.21,22 
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The EQ-5D-5L consists of two parts. The rst part consists of ve dimensions: 
mobility, self-care, usual activities, pain/discomfort and anxiety/depression. 
Each dimension is scored using a Likert scale. The combined scores of these 
ve dimensions are converted to the EQ-5D index score.22 The second part 
consists of a 20 cm visual analog scale (EQ-VAS) that has endpoints labeled 
“best imaginable health state” and “worst imaginable health state” anchored 
at 100 and 0, respectively. Respondents are asked to indicate how they rate 
their own health by writing down the number representing the point on the 
EQ-VAS which best represents their own health on that day.21,22 The EQ-5D-5L is 
embedded in this study protocol, as it is especially useful in combination with 
the economic evaluation that will be conducted in order to calculate utilities. 
Economic evaluation
The primary aim of the economic evaluation will be to estimate the societal 
costs of the strategy to perform a DAIR at day 9-10 and compare this with the 
costs of a continued non-surgical treatment strategy. Secondary aim will be to 
estimate the cost eectiveness of the surgical treatment compared with non-
surgical treatment (from a societal perspective), based on the primary measure 
of eectiveness (number of infections prevented). 
Cost eectiveness analyses (CEA) and cost utility analyses (CUA) based 
on EQ-5D-5L-dened utilities will be performed to describe the nancial 
consequences of both surgical and non-surgical treatment. All items of 
resource use will be collected at the patient level, using case report forms and 
the patient questionnaires Medical Consumption Questionnaire (iMCQ) and 
Productivity Cost Questionnaire (iPCQ). The iMCQ is a generic instrument for 
measuring medical costs. The questionnaire includes 31 questions related 
to frequently occurring contacts with health care providers.23 The iPCQ is a 
standardized generic instrument for measuring and valuing productivity 
losses. The questionnaire includes 12 questions divided into three modules 
measuring productivity losses of paid work due to absenteeism, presenteeism 
and productivity losses related to unpaid work.24,25 
The CEA and CUA integrate two quantities: the additional costs (or 
savings) of surgical treatment compared with non-surgical treatment and the 
additional health benets. Based on these two quantities the incremental cost 
eectiveness ratio is calculated, which is the dierence in costs divided by 
the dierence in eects. Results of the CEA will display the additional costs or 
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savings with surgical treatment in order to prevent one additional patient with 
an infection compared with non-surgical treatment. In the CUA, the impact on 
quality adjusted life year (QALY) will rely on the results based on the EQ-5D-
5L. Results of the CUA will display the additional costs or savings with surgical 
treatment in order to gain one QALY compared with non-surgical treatment. 
Health care will be valued using standard prices,26 with time and travel costs 
included in the CEA and CUA. Productivity losses will be valued using both 
the friction-cost method (primary analysis) and the human-capital method 
(sensitivity analysis). The time horizon will be 12 months; therefore, the analysis 
will not include discounting of costs and eects. Bootstrap resampling will be 
performed on the cost as well as on the cost and eect pairs in order to calculate 
condence intervals. Cost eectiveness acceptability curves will be plotted to 
estimate the probability of surgical treatment being more cost-eective than 
non-surgical treatment, for dierent amounts of money that a decision-maker 
may be willing to pay for one additional unit of eect (infection avoided or 
QALY).
Sample size
The power analysis is based on the assumption that 20% of patients with 
persistent wound leakage at day 9-10 will necessitate revision surgery. It is 
hypothesized that surgical treatment (DAIR at day 9-10) will prevent 50% of 
PJIs and consequently revision surgery compared with non-surgical treatment. 
In order to detect this 50% reduction with 80% power at a signicance level of 
0.05, 155 patients are required in the surgical treatment group and 155 in the 
non-surgical treatment group. With an expected dropout rate of approximately 
20%, a sample size of 194 patients per group is needed, making up a total 
required patient group of 388 patients. 
Statistical analysis
Descriptive statistics will be used to analyze patient characteristics. The primary 
outcome of the study is revision surgery for PJI within one year of index surgery 
(a binary variable). At least two measurements will be collected, namely at 
the time of randomization (at day 9-10) and one year after index surgery. The 
dependency of the measurements within the patient is our focal interest. To 
take into account other dependencies (e.g. the hospital in which the patient 
is treated), a multilevel logistic regression model with three levels will be used 
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to analyze the data. The three levels are hospitals, patients and measurements. 
As this study is designed as an RCT, every patient can be classied as a case 
(surgical treatment) or control (non-surgical treatment). The eect of the 
intervention will be controlled for relevant covariates such as age and gender. 
Intention-to-treat analyses will be conducted. Subanalyses will be performed 
for patients with wound leakage after THA and TKA separately, to gain insight 
into the eectiveness of the intervention. Moreover, subanalyses will be 
performed within both treatment groups to distinguish between patients who 
initially received non-surgical treatment but were treated with a DAIR at day 
16-17 versus patients who only received non-surgical treatment (non-surgical 
treatment group) and between patients who received one DAIR versus two 
DAIRs (surgical treatment group). 
For all analyses, a one–tailed signicant level of p <0.05 is considered to 
be statistically signicant. All statistical analyses will be performed using SPSS 
Version 24.0 for Windows (IBM, Armonk, New York, USA).
Ethics and dissemination
The Review Board of each participating hospital has examined and approved 
the local feasibility. The study will be conducted according to the principles of 
the Medical Research Involving Human Subjects Act (WMO), the Good Clinical 
Practice standard (GCP) and the Declaration of Helsinki. Eligible patients will 
be informed about the study and will sign an informed consent form in order 
to participate. Serious adverse events will be recorded and reported to an 
independent data and safety monitoring board. Auditing and monitoring will 
be carried out throughout the duration of the study. We began recruitment 
in February 2017 and expect to have completed recruitment by August 2018 
and completed data collection by August 2019. The results of this study will be 
published in international peer-reviewed scientic journals.
Discussion
Wound leakage is associated with PJI, with uid production as a symptom 
or a risk factor for infection. With increasing numbers of joint arthroplasties 
51938_Claudia_Löwik.indd   146 19-08-19   11:12
Design of the LEAK study
147
9
worldwide, the number of PJIs is rising as well. Without an evidence-based 
guideline, there is huge variation in clinical practice regarding the treatment 
of persistent wound leakage in the Netherlands and abroad, with both non-
surgical and surgical treatment modalities being used.11 The most recent 
PJI consensus meeting suggests ve to seven days of wound leakage as the 
threshold to perform a DAIR-procedure.16 However, this statement remains 
unproven and comparative studies on early surgical intervention (DAIR) versus 
non-surgical treatment are lacking. There is a need for an unambiguous clinical 
guideline to treat persistent wound leakage. 
Objective of the LEAK study is to determine the outcome of surgical 
treatment (DAIR at day 9-10) versus non-surgical treatment. Performing 
surgical treatment at day 9-10 is a compromise between the recommendation 
of the most recent PJI meeting and usual clinical practice in the Netherlands.16 
In preparation of designing this RCT, we performed a survey among Dutch 
orthopaedic surgeons to evaluate current Dutch orthopaedic care for persistent 
wound leakage after joint arthroplasty. As only 17.2% of Dutch orthopaedic 
surgeons started surgical treatment after 5-7 days of wound leakage and 44.1% 
after 10 days of wound leakage,11 we decided to perform surgical treatment at 
day 9-10 after joint arthroplasty. 
Based on the scarce literature available, the conservative assumption is 
that wound leakage is associated with revision for PJI in 20% of cases, and it is 
hypothesized that surgical treatment (DAIR on day 9-10) will reduce this to a 
10% revision rate for PJI, that is, a 50% reduction within one year of primary THA/
TKA compared with continued non-surgical treatment. It is hypothesized that 
in the long run (more than one year) even a larger reduction can be achieved, 
as many cases of PJI are caused by lower-virulence pathogens, and PJI within 
2-5 years is generally considered as related to the index surgery. In this study, 
participating patients will be followed-up for one year. This follow-up length is 
chosen because of restrictions from the subsidiary agency. Additional follow-
up will be done through the Dutch National Registry for Orthopaedic Implants 
(LROI). 
If the hypothesis as formulated in the LEAK study is conrmed, this will oer 
a rm body of evidence for the development of a guideline for treatment of 
prolonged wound leakage, eventually resulting in a lower percentage of PJIs 
and therefore a signicant improvement of physical functioning and health-
related quality of life for patients with prolonged wound leakage. Moreover, 
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from an economic perspective, it will lead to signicant cost savings in 
orthopaedic health care. It is estimated that in the Netherlands about 2200 
patients annually (4% of ± 55,000 THA/TKA) have wound leakage at day 9-10.2,6 
It is hypothesized that the number of patients needing revision surgery for 
PJI with non-surgical treatment will be 200-400 compared with 100-200 with 
surgical treatment at day 9-10 after index surgery. Costs of standard treatment 
are dicult to estimate due to large variations in current clinical practices. 
Costs of the study intervention (DAIR) are about €3,000. Additional savings 
include the avoided re-interventions, which amount to approximately €30,000 
per procedure. The hypothesized reduction in orthopaedic health care costs 
by implementing the LEAK study protocol is €300,000 per year nationwide. 
This reduction in health care costs will be even greater considering the fact 
that PJI may develop later than one year after index surgery. Furthermore, it is 
hypothesized that performing surgical treatment (DAIR at day 9-10) can reduce 
the productivity loss associated with reoperations and can reduce the costs 
associated with prolonged home care and informal care provided by relatives, 
which come in addition to the health care costs. 
During the design of the LEAK study, the project team discussed using a 
non-inferiority design. This was discarded, as it is estimated that the eect of 
surgical treatment is suciently large to provide evidence for the superiority of 
performing an early DAIR procedure. 
In conclusion, clinical practice for the treatment of persistent wound leakage 
varies considerably. The dilemma is that not all postoperative prolonged 
wound leakages are a proxy for PJI, but delaying surgical treatment for too long 
may result in undertreatment and development of a PJI. At the present time, 
the literature shows no evidence for superiority of surgical over non-surgical 
treatment. The results of the current study will contribute to development of 
evidence-based guidelines on the optimal treatment and treatment timing of 
persistent wound leakage after THA and TKA.
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